08:50 AM EDT, 08/21/2024 (MT Newswires) -- Monopar Therapeutics ( MNPR ) said Wednesday it has received clearance from Australia's Human Research Ethics Committee to start a phase 1 therapeutic trial of its radiopharmaceutical MNPR-101-Lu.
The MNPR-101-Lu trial will enroll patients with advanced solid cancers and will be a therapeutic follow-on study to its ongoing MNPR-101-Zr imaging and dosimetry trial, the radiopharma company said.
MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 with MNPR-101, the firm's humanized monoclonal antibody, Monopar said.
Price: 2.3900, Change: -0.09, Percent Change: -3.63